Print

Nitto Denko Corporation (XETRA: ND5.DE) Obtains US Patent for Antifibrotic Therapies with Molecular Targeting DDS Technology  
5/10/2012 11:02:14 AM

OSAKA, Japan--(BUSINESS WIRE)--Japan's leading diversified materials manufacturer, Nitto Denko Corporation (TOKYO:6988)(ISIN:JP3684000007), today announced that a basic patent regarding the company's epoch-making antifibrotic therapy has been successfully registered in the USA. Nitto Denko has been developing antifibrotic drugs in collaboration with Professor Yoshiro Niitsu at Sapporo Medical University since 2008, and has already been granted this patent in Japan, China and Australia.
//-->